The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
Diabetes and cancer are common diseases and are frequently diagnosed in the same individual. These patients need to take antidiabetic drugs while receiving antitumor drugs therapy. Recently, immunotherapy offers significant advances for cancer treatment. However, it is unclear whether antidiabetic d...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/2651790 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561994920624128 |
|---|---|
| author | Ze-Tao Zhan Lu Liu Ming-Zhen Cheng Yi Gao Wei-Jie Zhou |
| author_facet | Ze-Tao Zhan Lu Liu Ming-Zhen Cheng Yi Gao Wei-Jie Zhou |
| author_sort | Ze-Tao Zhan |
| collection | DOAJ |
| description | Diabetes and cancer are common diseases and are frequently diagnosed in the same individual. These patients need to take antidiabetic drugs while receiving antitumor drugs therapy. Recently, immunotherapy offers significant advances for cancer treatment. However, it is unclear whether antidiabetic drugs affect immunotherapy. Here, by employing syngeneic mouse colon cancer model and melanoma model, we studied the effects of 6 common antidiabetic drugs on anti-PD1 immune checkpoint inhibitor in tumor treatment, including acarbose, sitagliptin, metformin, glimepiride, pioglitazone, and insulin. We found that acarbose and sitagliptin enhanced the tumor inhibition of anti-PD1, and metformin had no effect on the tumor inhibition of anti-PD1, whereas glimepiride, pioglitazone, and insulin weakened the tumor inhibition of anti-PD1. Our study suggests that cancer patients receiving anti-PD1 antibody therapy need serious consideration when choosing antidiabetic drugs. In particular, acarbose significantly inhibited tumor growth and further enhanced the therapeutic effect of anti-PD1, which can be widely used in tumor therapy. Based on this study, further clinical trials are expected. |
| format | Article |
| id | doaj-art-9c2a83fd91994637ae0485dc431617e5 |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-9c2a83fd91994637ae0485dc431617e52025-02-03T01:23:39ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/2651790The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor TreatmentZe-Tao Zhan0Lu Liu1Ming-Zhen Cheng2Yi Gao3Wei-Jie Zhou4State Key Laboratory of Organ Failure ResearchState Key Laboratory of Organ Failure ResearchState Key Laboratory of Organ Failure ResearchGeneral Surgery CenterState Key Laboratory of Organ Failure ResearchDiabetes and cancer are common diseases and are frequently diagnosed in the same individual. These patients need to take antidiabetic drugs while receiving antitumor drugs therapy. Recently, immunotherapy offers significant advances for cancer treatment. However, it is unclear whether antidiabetic drugs affect immunotherapy. Here, by employing syngeneic mouse colon cancer model and melanoma model, we studied the effects of 6 common antidiabetic drugs on anti-PD1 immune checkpoint inhibitor in tumor treatment, including acarbose, sitagliptin, metformin, glimepiride, pioglitazone, and insulin. We found that acarbose and sitagliptin enhanced the tumor inhibition of anti-PD1, and metformin had no effect on the tumor inhibition of anti-PD1, whereas glimepiride, pioglitazone, and insulin weakened the tumor inhibition of anti-PD1. Our study suggests that cancer patients receiving anti-PD1 antibody therapy need serious consideration when choosing antidiabetic drugs. In particular, acarbose significantly inhibited tumor growth and further enhanced the therapeutic effect of anti-PD1, which can be widely used in tumor therapy. Based on this study, further clinical trials are expected.http://dx.doi.org/10.1155/2022/2651790 |
| spellingShingle | Ze-Tao Zhan Lu Liu Ming-Zhen Cheng Yi Gao Wei-Jie Zhou The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment Journal of Immunology Research |
| title | The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment |
| title_full | The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment |
| title_fullStr | The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment |
| title_full_unstemmed | The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment |
| title_short | The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment |
| title_sort | effects of 6 common antidiabetic drugs on anti pd1 immune checkpoint inhibitor in tumor treatment |
| url | http://dx.doi.org/10.1155/2022/2651790 |
| work_keys_str_mv | AT zetaozhan theeffectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT luliu theeffectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT mingzhencheng theeffectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT yigao theeffectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT weijiezhou theeffectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT zetaozhan effectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT luliu effectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT mingzhencheng effectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT yigao effectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment AT weijiezhou effectsof6commonantidiabeticdrugsonantipd1immunecheckpointinhibitorintumortreatment |